# T Cell Vaccination in Patients With Progressive Multiple Sclerosis

> **NCT01448252** · PHASE1,PHASE2 · COMPLETED · sponsor: **Hadassah Medical Organization** · enrollment: 30 (estimated)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides)
- **BIOLOGICAL:** T cell vaccination

## Key facts

- **NCT ID:** NCT01448252
- **Lead sponsor:** Hadassah Medical Organization
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05
- **Primary completion:** 2008-09
- **Final completion:** 2009-03
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2011-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01448252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01448252, "T Cell Vaccination in Patients With Progressive Multiple Sclerosis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01448252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*